ACD Pharma

Executive Summary

ACD Pharma is a Norwegian R&D company at the forefront of bacteriophage-based biocontrol, targeting antibiotic-resistant bacterial infections. Founded in 2005, the company achieved a milestone in 2018 by launching the world's first bacteriophage product for aquaculture. Currently, ACD Pharma is constructing a dedicated phage factory in Lofoten, which will scale production capabilities and support its expansion into both animal health and human medicine. The company's proprietary phage platform enables targeted elimination of pathogens without harming beneficial microbiota, offering a sustainable alternative to traditional antibiotics. The global rise of antimicrobial resistance presents a significant market opportunity for phage therapies, with applications in aquaculture, livestock, and human healthcare. ACD Pharma's first-mover advantage in aquaculture provides a validated commercial foundation, while its pipeline for human therapeutics addresses critical unmet needs. The construction of the Lofoten factory signals a shift from R&D to commercial-scale manufacturing, positioning the company for growth. With increasing regulatory support for phage-based products and growing awareness of antibiotic stewardship, ACD Pharma is well-positioned to become a key player in the biocontrol and phage therapy markets.

Upcoming Catalysts (preview)

• Q4 2026Completion of phage factory in Lofoten70% success
• Q2 2027Initiation of first-in-human clinical trial for phage therapy50% success
• Q3 2026Strategic partnership with major aquaculture or animal health company60% success